As of year-end 2024, Humira (adalimumab) biosimilars Hadlima, Yusimry and Simlandi offered the largest cost savings compared to the original, at an 85-86 percent lower WAC. Other biosimilars offered dual or multiple pricing options, where the WAC can vary heavily. Private label adalimumab also had a significantly lower WAC compared to the original, except for Cordavis' Humira. This statistic depicts the wholesale acquisition cost (WAC) of adalimumab in the United States, comparing originator drug Humira (AbbVie) to its biosimilars, as of Q4 2024.
Adalimumab wholesale acquisition cost (WAC) in the U.S. as of Q4 2024
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Samsung Bioepis. (October 10, 2024). Adalimumab wholesale acquisition cost (WAC) in the U.S. as of Q4 2024 [Graph]. In Statista. Retrieved December 04, 2024, from https://www.statista.com/statistics/1538539/humira-vs-biosimilars-wac-in-the-us/
Samsung Bioepis. "Adalimumab wholesale acquisition cost (WAC) in the U.S. as of Q4 2024." Chart. October 10, 2024. Statista. Accessed December 04, 2024. https://www.statista.com/statistics/1538539/humira-vs-biosimilars-wac-in-the-us/
Samsung Bioepis. (2024). Adalimumab wholesale acquisition cost (WAC) in the U.S. as of Q4 2024. Statista. Statista Inc.. Accessed: December 04, 2024. https://www.statista.com/statistics/1538539/humira-vs-biosimilars-wac-in-the-us/
Samsung Bioepis. "Adalimumab Wholesale Acquisition Cost (Wac) in The U.S. as of Q4 2024." Statista, Statista Inc., 10 Oct 2024, https://www.statista.com/statistics/1538539/humira-vs-biosimilars-wac-in-the-us/
Samsung Bioepis, Adalimumab wholesale acquisition cost (WAC) in the U.S. as of Q4 2024 Statista, https://www.statista.com/statistics/1538539/humira-vs-biosimilars-wac-in-the-us/ (last visited December 04, 2024)
Adalimumab wholesale acquisition cost (WAC) in the U.S. as of Q4 2024 [Graph], Samsung Bioepis, October 10, 2024. [Online]. Available: https://www.statista.com/statistics/1538539/humira-vs-biosimilars-wac-in-the-us/
